Speech-recognition firm replaces CEO amid class action suits
Facing several class action lawsuits and questions concerning revenue from its Korean business, Belgian speech-recognition firm Lernout & Hauspie announced that long-time president and CEO Gaston Bastiaens has stepped down. John Duerden, formerly
Facing several class action lawsuits and questions concerning revenue from its Korean business, Belgian speech-recognition firm Lernout & Hauspie announced that long-time president and CEO Gaston Bastiaens has stepped down.
John Duerden, formerly president and CEO of Dictaphone and L&Hs Healthcare Solutions Group (HSG), will take on leadership of the speech technologies firm. Robert Schwager, who served under Duerden as general manager of Dictaphones healthcare business and L&H HSG, will become president of L&H HSG. Bastiaens remains a board member.
Bastiaens had come under fire in recent months for focusing on growing L&Hs business through acquisitions rather than concentrating on its core speech recognition products. In fact, the company has been broadening its technology base in the face of stiff competition in the speech and voice technologies field, where the major players include IBM, Nuance Communications, SpeechWorks, and Philips Electronics.
Duerden plans to focus on better integrating Dictaphone and Dragon Systems into L&Hs operations. Dictaphone and Dragon Systems are among half a dozen companies acquired by L&H in the past year. Industry sources estimate that L&H achieved a 60% share of the $6 billion medical transcription market through the Dictaphone acquisition. Dictaphones healthcare division accounted for $11.2 million of the companys $155 million in revenue for second-quarter 2000.
L&H sales have fallen off everywhere except Korea. U.S. revenue totaled $48.2 million for second-quarter 2000, up from $18.7 million in second-quarter 1999, but the increase was attributed to revenue from Dictaphone and Dragon Systems. L&H stock has lost more than half its value since reaching a 52-week high of $72.50 in early spring. The stock closed at $29.75 per share Aug. 30. In addition, the firm filed a shelf registration statement with the Securities and Exchange Commission in early August to sell up to $250 million in stock to pay off bank debt and provide working capital.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
